Evotopin (BioDeep_00000017230)

 

Secondary id: BioDeep_00000226791, BioDeep_00000398847

human metabolite PANOMIX_OTCML-2023


代谢物信息卡片


(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione hydrochloride

化学式: C23H23N3O5.HCl (457.14044040000005)
中文名称: 盐酸拓扑替康, 盐酸托泊替康
谱图信息: 最多检出来源 Chinese Herbal Medicine(otcml) 2.7%

分子结构信息

SMILES: CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl
InChI: /m0./s1

描述信息

Topotecan Hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan selectively stabilizes topoisomerase I-DNA covalent complexes, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Camptothecin is a cytotoxic quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
See also: Topotecan (has active moiety).
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059004 - Topoisomerase I Inhibitors
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
D004791 - Enzyme Inhibitors
Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.
Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.

同义名列表

61 个代谢物同义名

(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione hydrochloride; 1H-Pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-, monohydrochloride, (S)-; 1H-Pyrano[3,7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, monohydrochloride, (4S)-; (S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3,4:6,7) indolizino(1,2-b) quinoline-3,14-(4H,12H)-dione Monohydrochloride; (4S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3,4:6,7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONEHYDROCHLORIDE (1:1); (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3,4:6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione monohydrochloride; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7]indolizino[l,2-b]quinoline-3,14(4H,12H)-dione monohydrochloride; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3,4:6,7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONEMONOHYDROCHLORIDE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-Pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione Hydrochloride; (S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; (S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dionehydrochloride; 10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride; (4S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3,4,6-7]INDOLIZINO[1,2-B]QUINOLINE-3,14(4H,12H)-DIONE; 9-[(DIMETHYLAMINO)METHYL]-10-HYDROXY-(20S)-CAMPTOTHECIN, HCL; 9-Dimethylaminomethyl-10-hydroxycamptothecin, HCl salt; 9 Dimethylaminomethyl 10 hydroxycamptothecin; 9-Dimethylaminomethyl-10-hydroxycamptothecin; Topotecan Monohydrochloride, (S)-Isomer; TOPOTECAN HYDROCHLORIDE [ORANGE BOOK]; TOPOTECAN HYDROCHLORIDE [USP-RS]; TOPOTECAN HYDROCHLORIDE [WHO-DD]; TOPOTECAN HYDROCHLORIDE (USP-RS); TOPOTECAN HYDROCHLORIDE [VANDF]; TOPOTECAN HYDROCHLORIDE (MART.); TOPOTECAN HYDROCHLORIDE [MART.]; Topotecan hydrochloride (USAN); topotecan hydrochloride (oral); Topotecan hydrochloride [USAN]; Nogitecan hydrochloride (JAN); NOGITECAN HYDROCHLORIDE [JAN]; TOPOTECAN HYDROCHLORIDE [MI]; Topotecan (as hydrochloride); Topotecan monohydrochloride; DGHHQBMTXTWTJV-BQAIUKQQSA-N; Hycamtin (TN) (GlaxoSmith); Hycamptamine hydrochloride; Topotecan (Hydrochloride); Hydrochloride, Topotecan; Hydrochloride, Nogitecan; Topotecan Hydrocholoride; Topotecan Hydrochloride; Nogitecan hydrochloride; TOPOTECANHYDROCHLORIDE; Topotecan Hospira; Topotecan Actavis; Potactasol (TN); Tox21_111478_1; Topotecan teva; nogitecan HCl; Hycamtin (TN); Topotecan Hcl; Tox21_111478; Hycamtamine; potactasol; Evotropin; Topotecan; Evotopin; E-89/001; Hycamtin; SKF 104864A (hydrochloride); NSC 609669 (hydrochloride)



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ali Rasouli, Qin Yu, Sepehr Dehghani-Ghahnaviyeh, Po-Chao Wen, Julia Kowal, Kaspar P Locher, Emad Tajkhorshid. Differential dynamics and direct interaction of bound ligands with lipids in multidrug transporter ABCG2. Proceedings of the National Academy of Sciences of the United States of America. 2023 01; 120(1):e2213437120. doi: 10.1073/pnas.2213437120. [PMID: 36580587]
  • Qun Niu, Wanxin Hou, Yinjie Yan, Shuzhang Sun, Yanyan Lin, Houshun Fang, Chunshuang Ma, Changsheng Dong, Yixuan Cheng, Yan Xu, Ming Ding, Shuxuan Wang, Zhiyan Cui, Yao Chen, Hegen Li, Hui Li, Ning Xiao. Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1. Biochimica et biophysica acta. Molecular basis of disease. 2022 12; 1868(12):166492. doi: 10.1016/j.bbadis.2022.166492. [PMID: 35850175]
  • Aveek Samanta, Saptadipa Banerjee, Tilak Raj Maity, Jangala Jahnavi, Siraj Datta. Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L. Protoplasma. 2022 Nov; 259(6):1455-1466. doi: 10.1007/s00709-022-01745-2. [PMID: 35195768]
  • Yin-Peng Bai, Cheng-Jie Yang, Nan Deng, Mi Zhang, Zhi-Jun Zhang, Lei Li, Yong Zhou, Xiong-Fei Luo, Chuan-Rui Xu, Bao-Qi Zhang, Yue Ma, Ying-Qian Liu. Design and synthesis of novel 7-ethyl-10-fluoro-20-O-(cinnamic acid ester)-camptothecin derivatives as potential high selectivity and low toxicity topoisomerase I inhibitors for hepatocellular carcinoma. Biochemical pharmacology. 2022 06; 200(?):115049. doi: 10.1016/j.bcp.2022.115049. [PMID: 35469784]
  • M J Del Sole, M Clausse, P Nejamkin, B Cancela, M Del Río, G Lamas, F Lubieniecki, J H Francis, D H Abramson, G Chantada, P Schaiquevich. Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment. Experimental eye research. 2022 05; 218(?):109026. doi: 10.1016/j.exer.2022.109026. [PMID: 35276184]
  • Philip J Kuehl, Christin M Yingling, Devon Dubose, Michael Burke, David A Revelli, Wenshu Chen, Wendy W Dye, Steven A Belinsky, Mathewos Tessema. Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug delivery. 2021 Dec; 28(1):767-775. doi: 10.1080/10717544.2021.1912209. [PMID: 33860729]
  • Zhiyong Zhang, Yan Pan, Yan Zhao, Mudan Ren, Yarui Li, Guifang Lu, Kaichun Wu, Shuixiang He. Topotecan-loaded thermosensitive nanocargo for tumor therapy: In vitro and in vivo analyses. International journal of pharmaceutics. 2021 Sep; 606(?):120871. doi: 10.1016/j.ijpharm.2021.120871. [PMID: 34246742]
  • Xuan Wang, Jim C Oates, Kristi L Helke, Gary S Gilkeson, Xian K Zhang. Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. Arthritis & rheumatology (Hoboken, N.J.). 2021 08; 73(8):1478-1488. doi: 10.1002/art.41685. [PMID: 33559345]
  • Tianjiao Zeng, Mingshi Xu, Wanli Zhang, Xiaofan Gu, Fangqing Zhao, Xuan Liu, Xiongwen Zhang. Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T lung cancer cells. Oncology reports. 2021 07; 46(1):. doi: 10.3892/or.2021.8100. [PMID: 34080652]
  • Jessica Sook Yuin Ho, Bobo Wing-Yee Mok, Laura Campisi, Tristan Jordan, Soner Yildiz, Sreeja Parameswaran, Joseph A Wayman, Natasha N Gaudreault, David A Meekins, Sabarish V Indran, Igor Morozov, Jessie D Trujillo, Yesai S Fstkchyan, Raveen Rathnasinghe, Zeyu Zhu, Simin Zheng, Nan Zhao, Kris White, Helen Ray-Jones, Valeriya Malysheva, Michiel J Thiecke, Siu-Ying Lau, Honglian Liu, Anna Junxia Zhang, Andrew Chak-Yiu Lee, Wen-Chun Liu, Sonia Jangra, Alba Escalera, Teresa Aydillo, Betsaida Salom Melo, Ernesto Guccione, Robert Sebra, Elaine Shum, Jan Bakker, David A Kaufman, Andre L Moreira, Mariano Carossino, Udeni B R Balasuriya, Minji Byun, Randy A Albrecht, Michael Schotsaert, Adolfo Garcia-Sastre, Sumit K Chanda, Emily R Miraldi, Anand D Jeyasekharan, Benjamin R TenOever, Mikhail Spivakov, Matthew T Weirauch, Sven Heinz, Honglin Chen, Christopher Benner, Juergen A Richt, Ivan Marazzi. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021 05; 184(10):2618-2632.e17. doi: 10.1016/j.cell.2021.03.051. [PMID: 33836156]
  • N S Dyrkheeva, A L Zakharenko, E S Novoselova, A A Chepanova, N A Popova, V P Nikolin, O A Luzina, N F Salakhutdinov, E I Ryabchikova, O I Lavrik. [Antitumor Activity of the Combination of Topotecan and Tyrosyl-DNA-Phosphodiesterase 1 Inhibitor on Model Krebs-2 Mouse Ascite Carcinoma]. Molekuliarnaia biologiia. 2021 Mar; 55(2):312-317. doi: 10.31857/s0026898421020051. [PMID: 33871444]
  • Yang Li, Chuchu Feng, Yantao Chen, Ke Huang, Chunmou Li, Xilin Xiong, Peng Li, Dunhua Zhou, Xiaomin Peng, Wenjun Weng, Xiaogeng Deng, Yaohao Wu, Jianpei Fang. Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series. Technology in cancer research & treatment. 2021 Jan; 20(?):15330338211041454. doi: 10.1177/15330338211041454. [PMID: 34569870]
  • R Xing, O Mustapha, T Ali, M Rehman, S S Zaidi, A Baseer, S Batool, M Mukhtiar, S Shafique, M Malik, S Sohail, Z Ali, F Zahid, A Zeb, F Shah, A Yousaf, F Din. Development, Characterization, and Evaluation of SLN-Loaded Thermoresponsive Hydrogel System of Topotecan as Biological Macromolecule for Colorectal Delivery. BioMed research international. 2021; 2021(?):9968602. doi: 10.1155/2021/9968602. [PMID: 34285920]
  • Esther Hee, Meng Kang Wong, Sheng Hui Tan, Zhang'E Choo, Chik Hong Kuick, Sharon Ling, Min Hwee Yong, Sudhanshi Jain, Derrick W Q Lian, Eileen H Q Ng, Yvonne F L Yong, Mee Hiong Ren, Nurfarhanah Syed Sulaiman, Sharon Y Y Low, Yong Wei Chua, Muhammad Fahmy Syed, Tony K H Lim, Shui Yen Soh, Prasad Iyer, Michaela S F Seng, Joyce C M Lam, Enrica E K Tan, Mei Yoke Chan, Ah Moy Tan, Yong Chen, Zhixiong Chen, Kenneth T E Chang, Amos Hong Pheng Loh. Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response. Cancer science. 2020 Oct; 111(10):3780-3792. doi: 10.1111/cas.14610. [PMID: 32777141]
  • Ying Li, Ying Liu, Bin Du, Genyang Cheng. Reshaping Tumor Blood Vessels to Enhance Drug Penetration with a Multistrategy Synergistic Nanosystem. Molecular pharmaceutics. 2020 09; 17(9):3151-3164. doi: 10.1021/acs.molpharmaceut.0c00077. [PMID: 32787273]
  • Yu-Mei Kang, Alexander Lan, Yen-Hua Huang, Kai-Mei Hsu, Yee Chao, Keng-Li Lan. Identification of key genes and pathways associated with topotecan treatment using multiple bioinformatics tools. Journal of the Chinese Medical Association : JCMA. 2020 May; 83(5):446-453. doi: 10.1097/jcma.0000000000000313. [PMID: 32243271]
  • Manisha Yadav, Swasti Dhagat, Jujjavarapu S Eswari. Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands. Current drug discovery technologies. 2020; 17(2):183-190. doi: 10.2174/1570163816666190307102033. [PMID: 30848204]
  • Liting Yan, Xiang Nan, Cunzheng Zhang, Haifang Wang, Xiaoyan Huang, Jun Hu, Yingqian Liu. Development of an enzyme‑linked immunosorbent assay for camptothecin. Molecular medicine reports. 2019 Aug; 20(2):959-966. doi: 10.3892/mmr.2019.10342. [PMID: 31173229]
  • Anna Birg Mitchell, Aksana Vasilyeva, Amar Gajjar, Victor M Santana, Clinton F Stewart. Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. Pediatric blood & cancer. 2019 04; 66(4):e27578. doi: 10.1002/pbc.27578. [PMID: 30548417]
  • Kasirawat Sawangrat, Shugo Yamashita, Akiko Tanaka, Masaki Morishita, Kosuke Kusamori, Hidemasa Katsumi, Toshiyasu Sakane, Akira Yamamoto. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter. Journal of pharmaceutical sciences. 2019 03; 108(3):1315-1325. doi: 10.1016/j.xphs.2018.10.043. [PMID: 30389568]
  • Philip J Kuehl, Marcie J Grimes, Devon Dubose, Michael Burke, David A Revelli, Andrew P Gigliotti, Steven A Belinsky, Mathewos Tessema. Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug delivery. 2018 Nov; 25(1):1127-1136. doi: 10.1080/10717544.2018.1469688. [PMID: 29779406]
  • Youcef M Rustum, Sreenivasulu Chintala, Farukh A Durrani, Arup Bhattacharya. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy. International journal of molecular sciences. 2018 Oct; 19(11):. doi: 10.3390/ijms19113378. [PMID: 30380599]
  • José Lopes-de-Araújo, Salette Reis, Cláudia Nunes. Topotecan effect on the structure of normal and cancer plasma membrane lipid models: A multi-model approach. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2018 Oct; 123(?):515-523. doi: 10.1016/j.ejps.2018.08.006. [PMID: 30086354]
  • Venkatesh Teja Banala, Shweta Sharma, Puja Barnwal, Sandeep Urandur, Ravi P Shukla, Naseer Ahmad, Naresh Mittapelly, Gitu Pandey, Monika Dwivedi, Navodayam Kalleti, Kalyan Mitra, Srikanta Kumar Rath, Ritu Trivedi, Prabhat Ranjan Mishra. Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site. Advanced healthcare materials. 2018 10; 7(19):e1800300. doi: 10.1002/adhm.201800300. [PMID: 30102470]
  • Yuta Naro, Nicholas Ankenbruck, Meryl Thomas, Yaniv Tivon, Colleen M Connelly, Laura Gardner, Alexander Deiters. Small Molecule Inhibition of MicroRNA miR-21 Rescues Chemosensitivity of Renal-Cell Carcinoma to Topotecan. Journal of medicinal chemistry. 2018 Jul; 61(14):5900-5909. doi: 10.1021/acs.jmedchem.7b01891. [PMID: 29993250]
  • Asma Yasmeen Khan, Gopinatha Suresh Kumar. Exploring the binding interaction of potent anticancer drug topotecan with human serum albumin: spectroscopic, calorimetric and fibrillation study. Journal of biomolecular structure & dynamics. 2018 Jul; 36(9):2463-2473. doi: 10.1080/07391102.2017.1359671. [PMID: 28760107]
  • Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, Harry J Long, Donald W Northfelt, Joel M Reid, Felix Boakye-Agyeman, Olumide Kayode, Karen S Flatten, Maria I Harrell, Elizabeth M Swisher, Guy G Poirier, Daniel Satele, Jake Allred, Janet L Lensing, Alice Chen, Jiuping Ji, Yiping Zang, Charles Erlichman, Paul Haluska, Scott H Kaufmann. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 02; 24(4):744-752. doi: 10.1158/1078-0432.ccr-17-1590. [PMID: 29138343]
  • Emanuelle Jesus Silva, Leonardo Gomes Souza, Luis Antonio Dantas Silva, Stephania Fleury Taveira, Raquel Ciffarello Guilger, Luciano Morais Liao, Luiz Henrique Keng Queiroz Junior, Mabio Joao Santana, Ricardo Neves Marreto. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties. Current drug delivery. 2018; 15(7):979-986. doi: 10.2174/1567201815666171215110026. [PMID: 29243576]
  • Sara M Federico, M Beth McCarville, Barry L Shulkin, Paul M Sondel, Jacquelyn A Hank, Paul Hutson, Michael Meagher, Aaron Shafer, Catherine Y Ng, Wing Leung, William E Janssen, Jianrong Wu, Shenghua Mao, Rachel C Brennan, Victor M Santana, Alberto S Pappo, Wayne L Furman. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Nov; 23(21):6441-6449. doi: 10.1158/1078-0432.ccr-17-0379. [PMID: 28939747]
  • Tao Wang, Liao Shen, Zhen Zhang, Haiyan Li, Ri Huang, Yadan Zhang, Dongqin Quan. A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption. Drug delivery. 2017 Nov; 24(1):1565-1573. doi: 10.1080/10717544.2017.1386730. [PMID: 29029577]
  • Guillem Pascual-Pasto, Nagore G Olaciregui, Javier A W Opezzo, Helena Castillo-Ecija, Maria Cuadrado-Vilanova, Sonia Paco, Ezequiel M Rivero, Monica Vila-Ubach, Camilo A Restrepo-Perdomo, Montserrat Torrebadell, Mariona Suñol, Paula Schaiquevich, Jaume Mora, Guillermo F Bramuglia, Guillermo L Chantada, Angel M Carcaboso. Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. Journal of controlled release : official journal of the Controlled Release Society. 2017 Oct; 264(?):34-44. doi: 10.1016/j.jconrel.2017.08.018. [PMID: 28830790]
  • Krishnansu S Tewari, Michael W Sill, Richard T Penson, Helen Huang, Lois M Ramondetta, Lisa M Landrum, Ana Oaknin, Thomas J Reid, Mario M Leitao, Helen E Michael, Philip J DiSaia, Larry J Copeland, William T Creasman, Frederick B Stehman, Mark F Brady, Robert A Burger, J Tate Thigpen, Michael J Birrer, Steven E Waggoner, David H Moore, Katherine Y Look, Wui-Jin Koh, Bradley J Monk. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet (London, England). 2017 Oct; 390(10103):1654-1663. doi: 10.1016/s0140-6736(17)31607-0. [PMID: 28756902]
  • João Hélio Venâncio, Lígia Marquez Andrade, Najla Locatelli Santos Esteves, Lara Barroso Brito, Marize Campos Valadares, Gisele Augusto Rodrigues Oliveira, Eliana Martins Lima, Ricardo Neves Marreto, Tais Gratieri, Stephânia Fleury Taveira. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers. The Journal of pharmacy and pharmacology. 2017 Oct; 69(10):1318-1326. doi: 10.1111/jphp.12772. [PMID: 28703281]
  • Roger Gilabert-Oriol, Lina Chernov, Malathi Anantha, Wieslawa H Dragowska, Marcel B Bally. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization. Drug delivery and translational research. 2017 08; 7(4):544-557. doi: 10.1007/s13346-017-0380-9. [PMID: 28432657]
  • Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jacqueline M Greer, Richard Piekarz, Judith E Karp, Keith Pratz, Michelle A Rudek. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. British journal of clinical pharmacology. 2017 08; 83(8):1688-1700. doi: 10.1111/bcp.13253. [PMID: 28156017]
  • Lina Chernov, Rebecca J Deyell, Malathi Anantha, Nancy Dos Santos, Roger Gilabert-Oriol, Marcel B Bally. Optimization of liposomal topotecan for use in treating neuroblastoma. Cancer medicine. 2017 Jun; 6(6):1240-1254. doi: 10.1002/cam4.1083. [PMID: 28544814]
  • Csaba Toth, Sarah Funke, Vanessa Nitsche, Anna Liverts, Viktoriya Zlachevska, Marcia Gasis, Constanze Wiek, Helmut Hanenberg, Csaba Mahotka, Peter Schirmacher, Sebastian Heikaus. The role of apoptosis repressor with a CARD domain (ARC) in the therapeutic resistance of renal cell carcinoma (RCC): the crucial role of ARC in the inhibition of extrinsic and intrinsic apoptotic signalling. Cell communication and signaling : CCS. 2017 05; 15(1):16. doi: 10.1186/s12964-017-0170-5. [PMID: 28464919]
  • Kathelijne Cjm Kraal, Elvira C van Dalen, Godelieve Am Tytgat, Berthe Lf Van Eck-Smit. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma. The Cochrane database of systematic reviews. 2017 Apr; 4(?):CD010349. doi: 10.1002/14651858.cd010349.pub2. [PMID: 28429876]
  • Kieuhoa T Vo, Erin E Karski, Nicole M Nasholm, Shelly Allen, Fabienne Hollinger, W Clay Gustafson, Janel R Long-Boyle, Stephen Shiboski, Katherine K Matthay, Steven G DuBois. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr; 8(14):23851-23861. doi: 10.18632/oncotarget.12904. [PMID: 27793021]
  • Zhao-Jie Chen, Zhen Zhang, Bei-Bei Xie, Hai-Yan Zhang. Development and evaluation of topotecan loaded solid lipid nanoparticles: A study in cervical cancer cell lines. Journal of photochemistry and photobiology. B, Biology. 2016 Dec; 165(?):182-188. doi: 10.1016/j.jphotobiol.2016.10.019. [PMID: 27816641]
  • Sensen Lin, Xiaodan Lyu, Jun Yu, Li Sun, Danyu Du, Yanqi Lai, Hongyang Li, Ying Wang, Luyong Zhang, Hongping Yin, Shengtao Yuan. MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2016 Sep; 23(10):1053-63. doi: 10.1016/j.phymed.2016.06.013. [PMID: 27444351]
  • Zeljko M Prijovich, Pierre-Alain Burnouf, Hua-Cheng Chou, Ping-Ting Huang, Kai-Chuan Chen, Tian-Lu Cheng, Yu-Lin Leu, Steve R Roffler. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. Molecular pharmaceutics. 2016 Apr; 13(4):1242-50. doi: 10.1021/acs.molpharmaceut.5b00771. [PMID: 26824303]
  • Paula Taich, Flavio Requejo, Marcelo Asprea, Mariana Sgroi, Pierre Gobin, David H Abramson, Guillermo Chantada, Paula Schaiquevich. Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. PloS one. 2016; 11(3):e0151343. doi: 10.1371/journal.pone.0151343. [PMID: 26959658]
  • Marie Morfouace, Satish Cheepala, Sadhana Jackson, Yu Fukuda, Yogesh T Patel, Soghra Fatima, Daisuke Kawauchi, Anang A Shelat, Clinton F Stewart, Brian P Sorrentino, John D Schuetz, Martine F Roussel. ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. Cancer research. 2015 Sep; 75(18):3879-89. doi: 10.1158/0008-5472.can-15-0030. [PMID: 26199091]
  • Lot A Devriese, Petronella Els O Witteveen, Marja Mergui-Roelvink, Deborah A Smith, Lionel D Lewis, David S Mendelson, Yung-Jue Bang, Hyun Choel Chung, Mohammed M Dar, Alwin D R Huitema, Jos H Beijnen, Emile E Voest, Jan H M Schellens. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. British journal of clinical pharmacology. 2015 Aug; 80(2):253-66. doi: 10.1111/bcp.12606. [PMID: 25677219]
  • Elena V Rosca, Michael Wright, Roman Gonitel, Wladyslaw Gedroyc, Andrew D Miller, Maya Thanou. Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors. Molecular pharmaceutics. 2015 May; 12(5):1335-46. doi: 10.1021/mp5002679. [PMID: 25826624]
  • Christopher Jedeszko, Marta Paez-Ribes, Teresa Di Desidero, Shan Man, Christina R Lee, Ping Xu, Georg A Bjarnason, Guido Bocci, Robert S Kerbel. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science translational medicine. 2015 Apr; 7(282):282ra50. doi: 10.1126/scitranslmed.3010722. [PMID: 25855496]
  • Gulsah Congur, Arzum Erdem, Fehmi Mese. Electrochemical investigation of the interaction between topotecan and DNA at disposable graphite electrodes. Bioelectrochemistry (Amsterdam, Netherlands). 2015 Apr; 102(?):21-8. doi: 10.1016/j.bioelechem.2014.11.003. [PMID: 25461757]
  • A M C Mavinkurve-Groothuis, M M van den Heuvel-Eibrink, G A Tytgat, H van Tinteren, G Vujanic, K L P Pritchard-Jones, L Howell, N Graf, C Bergeron, T Acha, S Catania, F Spreafico. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). Pediatric blood & cancer. 2015 Apr; 62(4):598-602. doi: 10.1002/pbc.25357. [PMID: 25546733]
  • Kyle D Fugit, Amar Jyoti, Meenakshi Upreti, Bradley D Anderson. Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method. Journal of controlled release : official journal of the Controlled Release Society. 2015 Jan; 197(?):10-9. doi: 10.1016/j.jconrel.2014.10.011. [PMID: 25456833]
  • Ming Zhao, Ruth A Gjerset. Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PloS one. 2015; 10(8):e0134929. doi: 10.1371/journal.pone.0134929. [PMID: 26248194]
  • Primo N Lara, James Moon, Mary W Redman, Thomas J Semrad, Karen Kelly, Jeffrey W Allen, Barbara J Gitlitz, Philip C Mack, David R Gandara. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jan; 10(1):110-5. doi: 10.1097/jto.0000000000000385. [PMID: 25490004]
  • Hung C Tran, Sharon Gardner, Howard L Weiner, Leonard F Liebes, Jonathan L Finlay. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2014 Jun; 20(3):229-32. doi: 10.1177/1078155213494940. [PMID: 23929729]
  • Dhaval K Shah, Joseph P Balthasar. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. International journal of pharmaceutics. 2014 Apr; 465(1-2):228-38. doi: 10.1016/j.ijpharm.2014.01.038. [PMID: 24508555]
  • Kyle D Fugit, Bradley D Anderson. Dynamic, nonsink method for the simultaneous determination of drug permeability and binding coefficients in liposomes. Molecular pharmaceutics. 2014 Apr; 11(4):1314-25. doi: 10.1021/mp400765n. [PMID: 24628304]
  • Paula Taich, Alejandro Ceciliano, Emiliano Buitrago, Claudia Sampor, Adriana Fandino, Francisco Villasante, Evandro Lucena, Livia Romero, Guillermo L Chantada, Paula Schaiquevich. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology. 2014 Apr; 121(4):889-97. doi: 10.1016/j.ophtha.2013.10.045. [PMID: 24359624]
  • Dhaval K Shah, Joseph P Balthasar. Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. Journal of pharmacokinetics and pharmacodynamics. 2014 Feb; 41(1):55-69. doi: 10.1007/s10928-013-9346-9. [PMID: 24368689]
  • Ling Ye, Jian Shi, Shanhe Wan, Xiaoshan Yang, Ying Wang, Jiajie Zhang, Dayong Zheng, Zhongqiu Liu. Development and validation of a liquid chromatography-tandem mass spectrometry method for topotecan determination in beagle dog plasma and its application in a bioequivalence study. Biomedical chromatography : BMC. 2013 Nov; 27(11):1532-9. doi: 10.1002/bmc.2956. [PMID: 23788247]
  • Ning Li, Yuanyuan Song, Ping Du, Yinchen Shen, Jianliang Yang, Lin Gui, Shuai Wang, Jianfei Wang, Yan Sun, Xiaohong Han, Yuankai Shi. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013 Oct; 67(8):801-6. doi: 10.1016/j.biopha.2013.08.002. [PMID: 24074809]
  • Alessandra Rovida, Vittoria Castiglioni, Alessandra Decio, Valentina Scarlato, Eugenio Scanziani, Raffaella Giavazzi, Marta Cesca. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. Molecular cancer therapeutics. 2013 Oct; 12(10):2237-47. doi: 10.1158/1535-7163.mct-13-0244. [PMID: 23918831]
  • Corbin Bachmeier, Gary M Levin, David Beaulieu-Abdelahad, Jon Reed, Michael Mullan. Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. Journal of pharmaceutical sciences. 2013 Oct; 102(10):3838-43. doi: 10.1002/jps.23680. [PMID: 23897419]
  • Yoshiki Matsuda, Yoshihiro Konno, Takashi Hashimoto, Mika Nagai, Takayuki Taguchi, Masahiro Satsukawa, Shinji Yamashita. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats. Drug metabolism and disposition: the biological fate of chemicals. 2013 Aug; 41(8):1514-21. doi: 10.1124/dmd.113.051680. [PMID: 23686319]
  • Krupa J Patel, Olivier Trédan, Ian F Tannock. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer chemotherapy and pharmacology. 2013 Jul; 72(1):127-38. doi: 10.1007/s00280-013-2176-z. [PMID: 23680920]
  • Amit K Tiwari, Rong Zhang, James M Gallo. Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. Molecular cancer therapeutics. 2013 Jul; 12(7):1343-55. doi: 10.1158/1535-7163.mct-13-0100. [PMID: 23635651]
  • F Bauer, B Filipiak-Pittroff, A Wawer, I von Luettichau, S Burdach. Escalating topotecan in combination with treosulfan has acceptable toxicity in advanced pediatric sarcomas. Pediatric hematology and oncology. 2013 May; 30(4):263-72. doi: 10.3109/08880018.2013.777948. [PMID: 23509879]
  • Fan Lin, Lisette Hoogendijk, Levi Buil, Jos H Beijnen, Olaf van Tellingen. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. European journal of cancer (Oxford, England : 1990). 2013 May; 49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028. [PMID: 23422148]
  • Ning Li, Xiaohong Han, Jianliang Yang, Lin Gui, Yuanyuan Song, Ping Du, Yuankai Shi. Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2013 Mar; 76(?):252-6. doi: 10.1016/j.jpba.2012.12.033. [PMID: 23354352]
  • Emiliano Buitrago, María José Del Sole, Ana Torbidoni, Adriana Fandino, Marcelo Asprea, J O Croxatto, Guillermo L Chantada, Guillermo F Bramuglia, Paula Schaiquevich. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. Experimental eye research. 2013 Mar; 108(?):103-9. doi: 10.1016/j.exer.2013.01.002. [PMID: 23333535]
  • ChunLei Li, Xi Zhao, YaJuan Wang, HanYu Yang, HaiXia Li, Huan Li, Wei Tian, Jian Yang, JingXia Cui. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan. International journal of pharmaceutics. 2013 Feb; 443(1-2):17-25. doi: 10.1016/j.ijpharm.2013.01.012. [PMID: 23318366]
  • A Susloparova, D Koppenhöfer, X T Vu, M Weil, S Ingebrandt. Impedance spectroscopy with field-effect transistor arrays for the analysis of anti-cancer drug action on individual cells. Biosensors & bioelectronics. 2013 Feb; 40(1):50-6. doi: 10.1016/j.bios.2012.06.006. [PMID: 22795530]
  • Nilesh A Patankar, Dawn Waterhouse, Dita Strutt, Malathi Anantha, Marcel B Bally. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Investigational new drugs. 2013 Feb; 31(1):46-58. doi: 10.1007/s10637-012-9832-8. [PMID: 22615060]
  • Denisa Darsova, Pavel Pochop, Jiri Uhlik, Eva Klapkova, Hundie Tesfaye, Daniela Kodetova, Jan Lestak, Josef Malis, Ludek Vajner. Topotecan vitreous and plasma levels and retinal toxicity after transcorneal intravitreal delivery in healthy albino rabbits: alternative retinoblastoma treatment. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2012 Dec; 156(4):318-23. doi: 10.5507/bp.2011.068. [PMID: 22660213]
  • Tomasz Bączek, Lucyna Konieczna, Mariusz Belka, Lucyna Maciejka-Kapuścińska, Jakub Wiśniewski, Maciej Niedźwiecki, Anna Balcerska, Elżbieta Adamkiewicz-Drożyńska, Jacek Wachowiak. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. Journal of pharmaceutical and biomedical analysis. 2012 Nov; 70(?):330-6. doi: 10.1016/j.jpba.2012.05.012. [PMID: 22658903]
  • Anthony G McCluskey, Robert J Mairs, Mathias Tesson, Sally L Pimlott, John W Babich, Mark N Gaze, Sue Champion, Marie Boyd. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012 Jul; 53(7):1146-54. doi: 10.2967/jnumed.111.095943. [PMID: 22689924]
  • Mira Kim, Kwangsu Ock, Keunchang Cho, Sang-Woo Joo, So Yeong Lee. Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media. Chemical communications (Cambridge, England). 2012 May; 48(35):4205-7. doi: 10.1039/c2cc30679d. [PMID: 22441353]
  • Masanori Nakakariya, Midori Ono, Nobuyuki Amano, Toshiya Moriwaki, Kazuya Maeda, Yuichi Sugiyama. In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2012 Mar; 40(3):602-9. doi: 10.1124/dmd.111.042101. [PMID: 22190695]
  • Chunlei Li, Caixia Wang, Hanyu Yang, Xi Zhao, Na Wei, Jingxia Cui. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. The Journal of pharmacy and pharmacology. 2012 Mar; 64(3):372-82. doi: 10.1111/j.2042-7158.2011.01422.x. [PMID: 22309269]
  • Liping Yao, Xiuhua Zhao, Qingyong Li, Yuangang Zu, Yujie Fu, Baishi Zu, Xiangdong Meng, Chen Liu. In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity. International journal of pharmaceutics. 2012 Feb; 423(2):586-8. doi: 10.1016/j.ijpharm.2011.11.031. [PMID: 22193057]
  • Paula Schaiquevich, Emiliano Buitrago, Alejandro Ceciliano, Adriana C Fandino, Marcelo Asprea, Sergio Sierre, David H Abramson, Guillermo F Bramuglia, Guillermo L Chantada. Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina (Philadelphia, Pa.). 2012 Feb; 32(2):387-95. doi: 10.1097/iae.0b013e31821e9f8a. [PMID: 21878842]
  • Maryann Kwa, Robert Baumgartner, Linda Shavit, Irina Barash, Jeffrey Michael, Igor Puzanov, Juri Kopolovic, Ora Rosengarten, Stephanie Blank, John P Curtin, Alberto Gabizon, Franco Muggia. Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?. The oncologist. 2012; 17(12):1534-40. doi: 10.1634/theoncologist.2011-0422. [PMID: 22622146]
  • Shivaani Kummar, Alice Chen, Jiuping Ji, Yiping Zhang, Joel M Reid, Matthew Ames, Lee Jia, Marcie Weil, Giovanna Speranza, Anthony J Murgo, Robert Kinders, Lihua Wang, Ralph E Parchment, John Carter, Howard Stotler, Larry Rubinstein, Melinda Hollingshead, Giovanni Melillo, Yves Pommier, William Bonner, Joseph E Tomaszewski, James H Doroshow. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer research. 2011 Sep; 71(17):5626-34. doi: 10.1158/0008-5472.can-11-1227. [PMID: 21795476]
  • L G Souza, E J Silva, A L L Martins, M F Mota, R C Braga, E M Lima, M C Valadares, S F Taveira, R N Marreto. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2011 Sep; 79(1):189-96. doi: 10.1016/j.ejpb.2011.02.012. [PMID: 21352915]
  • Eleni Andreopoulou, Thomas Chen, Leonard Liebes, John Curtin, Stephanie Blank, Robert Wallach, Howard Hochster, Franco Muggia. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. Cancer chemotherapy and pharmacology. 2011 Aug; 68(2):457-63. doi: 10.1007/s00280-010-1510-y. [PMID: 21069334]
  • T Chekrine, B De Bari, P Cassier, M Kulisa, O Chapet, F Mornex. [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2011 Jun; 15(3):250-3. doi: 10.1016/j.canrad.2010.11.013. [PMID: 21420344]
  • Qin Cheng, Yu Du, Kangbing Wu, Jianwei Chen, Yikai Zhou. Electrochemical detection of anticancer drug topotecan using nano-acetylene black film. Colloids and surfaces. B, Biointerfaces. 2011 May; 84(1):135-9. doi: 10.1016/j.colsurfb.2010.12.027. [PMID: 21255983]
  • Dhaval K Shah, Joseph P Balthasar. Physiologically based pharmacokinetic model for topotecan in mice. Journal of pharmacokinetics and pharmacodynamics. 2011 Feb; 38(1):121-42. doi: 10.1007/s10928-010-9181-1. [PMID: 21104004]
  • Akinori Sato, Takako Asano, Akio Horiguchi, Keiichi Ito, Makoto Sumitomo, Tomohiko Asano. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncology research. 2011; 19(5):217-23. doi: 10.3727/096504011x12970940207841. [PMID: 21542457]
  • Saleh A Bakheet. Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan. Oxidative medicine and cellular longevity. 2011; 2011(?):824597. doi: 10.1155/2011/824597. [PMID: 21904648]
  • Theodoros Daladimos, Evangelos Theotikos, Aggelos Athanasopoulos, George Tsakonas, Athanasios Karabelis, Nikolaos Mylonakis, Christos Kosmas. Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report. Anti-cancer drugs. 2011 Jan; 22(1):111-4. doi: 10.1097/cad.0b013e328340189a. [PMID: 20881835]
  • JingXia Cui, ChunLei Li, CaiXia Wang, YanHui Li, Lan Zhang, Li Zhang, Xian Xiu, YongFeng Li, Na Wei. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?. International journal of pharmaceutics. 2010 Oct; 399(1-2):31-6. doi: 10.1016/j.ijpharm.2010.07.050. [PMID: 20678563]
  • Hervé Rubie, Birgit Geoerger, Didier Frappaz, Antonin Schmitt, Pierre Leblond, Anna Ndiaye, Isabelle Aerts, Marie-Cécile Le Deley, Jean-Claude Gentet, Angelo Paci, Pascal Chastagner, Nathalie Dias, Latifa Djafari, Marlène Pasquet, Etienne Chatelut, Judith Landman-Parker, Nadège Corradini, Gilles Vassal. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European journal of cancer (Oxford, England : 1990). 2010 Oct; 46(15):2763-70. doi: 10.1016/j.ejca.2010.05.004. [PMID: 20558056]
  • Robert J Morgan, Timothy Synold, Adam Mamelak, Dean Lim, Zaid Al-Kadhimi, Przemyslaw Twardowski, Lucille Leong, Warren Chow, Kim Margolin, Stephen Shibata, George Somlo, Yun Yen, Paul Frankel, James H Doroshow. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer chemotherapy and pharmacology. 2010 Oct; 66(5):927-33. doi: 10.1007/s00280-010-1242-z. [PMID: 20107803]
  • Rudel A Saunders, Kazuyuki Fujii, Leah Alabanza, Roald Ravatn, Tsunekazu Kita, Kazuya Kudoh, Masahiro Oka, Khew-Voon Chin. Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan. Biochemical pharmacology. 2010 Aug; 80(3):362-9. doi: 10.1016/j.bcp.2010.04.015. [PMID: 20416282]
  • Emiliano Buitrago, Christian Höcht, Guillermo Chantada, Adriana Fandiño, Elliot Navo, David H Abramson, Paula Schaiquevich, Guillermo F Bramuglia. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. Experimental eye research. 2010 Jul; 91(1):9-14. doi: 10.1016/j.exer.2010.03.009. [PMID: 20307538]
  • Angel M Carcaboso, Mohamed A Elmeliegy, Jun Shen, Stephen J Juel, Ziwei M Zhang, Christopher Calabrese, Lorraine Tracey, Christopher M Waters, Clinton F Stewart. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer research. 2010 Jun; 70(11):4499-508. doi: 10.1158/0008-5472.can-09-4264. [PMID: 20460504]
  • Angel M Carcaboso, Diego A Chiappetta, Javier A W Opezzo, Christian Höcht, Adriana C Fandiño, J Oscar Croxatto, Modesto C Rubio, Alejandro Sosnik, David H Abramson, Guillermo F Bramuglia, Guillermo L Chantada. Episcleral implants for topotecan delivery to the posterior segment of the eye. Investigative ophthalmology & visual science. 2010 Apr; 51(4):2126-34. doi: 10.1167/iovs.09-4050. [PMID: 19834044]
  • Kelly K Curtis, Jean T Hartney, Roxanne C Jewell, Jung W Park, Peter F Lebowitz, Pamela P Griffin, Mitesh J Borad, Tom R Fitch, Donald W Northfelt. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. Journal of clinical pharmacology. 2010 Mar; 50(3):268-75. doi: 10.1177/0091270009343699. [PMID: 19808951]
  • M R Litzow, P P Peethambaram, S L Safgren, G L Keeney, S M Ansell, A Dispenzieri, M A Elliott, D A Gastineau, M A Gertz, D J Inwards, M Q Lacy, I N M Micallef, L F Porrata, W L Lingle, L C Hartmann, M H Frost, B A Barrette, H J Long, V J Suman, J M Reid, M M Ames, S H Kaufmann. Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone marrow transplantation. 2010 Mar; 45(3):490-7. doi: 10.1038/bmt.2009.181. [PMID: 19648970]
  • Hee Seung Kim, Noh Hyun Park, Sokbom Kang, Sang-Soo Seo, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Soon-Beom Kang. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. The journal of obstetrics and gynaecology research. 2010 Feb; 36(1):86-93. doi: 10.1111/j.1447-0756.2009.01101.x. [PMID: 20178532]